Marie Holmqvist

Dr. Marie Holmqvist

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
ILIngrid E. Lundberg
Ingrid E. Lundberg
MFManabu Fujimoto
Manabu Fujimoto
JVJiri Vencovsky
Jiri Vencovsky
RARohit Aggarwal
Rohit Aggarwal
MHMarie Holmqvist
Marie Holmqvist
FMFrederick W. Miller
Frederick W. Miller

25 February 2021 in Rheumatology
Verified
Journal Article
Open access
PDF file
MBMajd Bairkdar
Majd Bairkdar
MRMarios Rossides
Marios Rossides
HWHelga Westerlind
Helga Westerlind
RHRoger Hesselstrand
Roger Hesselstrand
EAElizabeth V Arkema
Elizabeth V Arkema
MHMarie Holmqvist
Marie Holmqvist
Objectives: We aimed to conduct a systematic review and meta-analysis on the incidence and prevalence of SSc covering the entire literature. Methods: This study followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement of 2009. We conducted a systematic search in MEDLINE, Web of Science and Embase to identify articles reporting incidence and/or prevalence of SSc. Two authors conducted the search, reviewed articles for inclusion and extracted relevant data. We used random-effects models to estimate the pooled prevalence and incidence of SSc and performed subgroup analyses by sex, case definition and region to investigate heterogeneity. We explored the association between calendar period and reported estimates using meta-regression. Results: Among 6983 unique records identified, we included 61 studies of prevalence and 39 studies of incidence in the systematic review. The overall pooled prevalence of SSc was 17.6 (95% CI 15.1, 20.5) per 100 000 and the overall pooled incidence rate of SSc was 1.4 (95% CI 1.1, 1.9) per 100 000 person-years. We observed significant regional variations in reported estimates; studies conducted in North America reported considerably higher estimates than other regions. The pooled incidence and prevalence in women were five times higher than in men. More recent studies reported higher estimates than older ones. Conclusion: In this comprehensive review of the incidence and prevalence of SSc across the world, there was large heterogeneity among estimates, which should be taken into consideration when interpreting the results.

3 October 2012 in JAMA
Verified
Journal Article
Open access
PDF file
MHMarie Holmqvist
Marie Holmqvist
MNMartin Neovius
Martin Neovius
JEJonas Eriksson
Jonas Eriksson
ÄMÄngla Mantel
Ängla Mantel
SWSolveig Wållberg-Jonsson
Solveig Wållberg-Jonsson
JAJohan Askling
Johan Askling
Acute inflammation promotes a hypercoagulable state that may increase the risk of deep vein thrombosis (DVT) and pulmonary embolism.1 In chronic inflammatory disease such as rheumatoid arthritis (RA), procoagulatory factors are up-regulated.2,3 Few studies have assessed how this theoretical inflammation-induced risk of venous thromboembolism (VTE) translates into risk for clinical events in patients with RA.4-9

22 November 2010 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
MHMarie Holmqvist
Marie Holmqvist
SWS. Wedrén
S. Wedrén
LJL. T. H. Jacobsson
L. T. H. Jacobsson
LKL. Klareskog
L. Klareskog
FNF. Nyberg
F. Nyberg
JAJ. Askling
J. Askling
Abstract.  Holmqvist ME, Wedrén S, Jacobsson LTH, Klareskog L, Nyberg F, Rantapää‐Dahlqvist S, Alfredsson L, Askling J (Institute of Environmental Medicine, Karolinska Institutet, Stockholm; Karolinska Institutet/Karolinska Hospital, Stockholm; Malmö University Hospital, Malmö; AstraZeneca R&D, Mölndal; and Umeå University Hospital, Umeå, Sweden) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010; 268: 578–585.The risk of ischaemic heart disease (IHD), and in particular myocardial infarction (MI), is increased amongst patients with established rheumatoid arthritis (RA). Few studies have included contemporary patients with RA. We recently reported that the risk of IHD is not elevated before the onset of RA symptoms. However, when, in relation to RA diagnosis, the risk is increased is unknown.Objective.  To assess the risk of MI and other IHD events amongst patients diagnosed with RA during the last decade and within 18 months following RA symptom onset, compared to the general population, by time since RA diagnosis, year of RA diagnosis and by rheumatoid factor (RF) status.Methods and patients.  A Swedish inception cohort of RA (n = 7469) diagnosed between 1995 and 2006 and a matched general population comparator cohort (n = 37 024), was identified and linked to national registers of morbidity and mortality from IHD. Relative risks (RRs) of MI and other IHD events were estimated using Cox regression.Results.  During follow‐up, 233 patients with RA and 701 controls developed a first MI, corresponding to an overall RR of MI of 1.6 (95% confidence interval 1.4, 1.9). Increased risks of MI were already detected within 1–4 years following RA diagnosis, as well as in patients diagnosed with RA during the last 5 years, in RF‐negative patients and for transmural as well as nontransmural MIs.Conclusions.  MI risk increases rapidly following RA diagnosis, suggesting the importance of additional mechanisms other than atherosclerosis. The elevated short‐term risk is present amongst patients diagnosed in recent years, underscoring the importance of MI prevention from the time of RA diagnosis.

21 September 2021 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
VKVanessa L. Kronzer
Vanessa L. Kronzer
BKBradly A. Kimbrough
Bradly A. Kimbrough
CCCynthia S. Crowson
Cynthia S. Crowson
JDJohn M. Davis
John M. Davis
MHMarie Holmqvist
Marie Holmqvist
FEFloranne C. Ernste
Floranne C. Ernste

18 December 2025 in Science
Verified
Journal Article
Closed access
MÁMaría Bueno Álvez
María Bueno Álvez
SBSofia Bergström
Sofia Bergström
JKJosefin Kenrick
Josefin Kenrick
EJEmil Johansson
Emil Johansson
MAMikael Aberg
Mikael Aberg
MUMathias Uhlen
Mathias Uhlen
The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. In this study, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and body mass index, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8262 individuals and up to 5416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.